Valuation: argenx SE

Market Cap 60.62B 54.93B 50.81B 45.84B 86.39B 5,716B 89.44B 610B 242B 3,053B 227B 223B 9,692B P/E 2026 *
32.8x
P/E 2027 * 27.3x
Enterprise Value 56.85B 51.51B 47.65B 42.99B 81.02B 5,360B 83.87B 572B 227B 2,863B 213B 209B 9,089B EV / Sales 2026 *
8.77x
EV / Sales 2027 * 6.85x
Free-Float
100%
Yield 2026 *
0.07%
Yield 2027 * 0.1%
1 day-0.92%
1 week+7.67%
Current month+8.82%
1 month+22.24%
3 months+16.44%
6 months+27.82%
Current year+22.54%
1 week 824.2
Extreme 824.2
896
1 month 724.4
Extreme 724.4
896
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 13.25
Extreme 13.25
925
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/25 Sell

Chief Executive Officer

2,000 0.0032%
23/11/25 Sell

Director

4,680 0.0076%
23/11/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%+7.67%+14.26%+90.92% 60.62B
-2.69%-0.48%+51.67%+69.09% 66.33B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
-4.38%-1.85%+35.56%-4.22% 24.45B
Average -0.99%-0.14%+37.54%+169.35% 43B
Weighted average by Cap. -1.03%+0.08%+37.13%+152.75%

Financials

2026 *2027 *
Net sales 6.48B 5.88B 5.44B 4.9B 9.24B 611B 9.57B 65.29B 25.89B 327B 24.33B 23.82B 1,037B 7.98B 7.23B 6.69B 6.03B 11.37B 752B 11.77B 80.33B 31.85B 402B 29.94B 29.3B 1,276B
Net income 1.82B 1.65B 1.52B 1.38B 2.59B 172B 2.68B 18.32B 7.26B 91.63B 6.83B 6.68B 291B 2.14B 1.94B 1.8B 1.62B 3.06B 202B 3.16B 21.6B 8.56B 108B 8.05B 7.88B 343B
Net Debt -3.77B -3.42B -3.16B -2.85B -5.38B -356B -5.57B -37.99B -15.06B -190B -14.16B -13.86B -603B -5.93B -5.38B -4.97B -4.49B -8.46B -559B -8.75B -59.74B -23.69B -299B -22.26B -21.79B -949B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
13/11/26 €878.40 -0.92% 64,677
12/11/26 €886.60 +1.28% 111,898
11/11/26 €875.40 +1.30% 54,895
10/11/26 €864.20 +1.22% 95,099
09/11/26 €853.80 +4.66% 108,220
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
969.32USD
Average target price
1,119.00USD
Spread / Average Target
+15.44%
  1. Stock Market
  2. Stocks
  3. ARGX Stock